In Egypt

Sofosbuvir (SOF) in combination with Dataclasvir (DCV) is the broadly used DAAs with excellent therapeutic profile. This study is designed to explore the relation between IL28B/TLR4 genetic variants and each of the followings; HCC development post SOF/DCV treatment

progression to HCC in naïve patients and SOF/DCV therapy outcome. A total of 493 blood samples were collected (controls (

n

 = 70); HCV patients treated with SOF/DCV (

n

 = 252) of whom 65 patients developed HCC

187 patients didn't develop HCC (125 responders

62 relapsers); naïve HCV patients (

n

 = 171) had early (

n

 = 48)

late liver fibrosis (

n

 = 21) and HCC (

n

 = 102)). Both SNPs were genotyped using a TaqMan 5′ allelic discrimination assay. At IL28B rs12979860 SNP

the C allele was significantly correlating with the response rate more than T allele (OR 1.9

95% CI 1.29–2.9

p

 = 0.004)

while at TLR4 rs4986791 SNP

no association was found (OR 6.5

95% 0.57–75.28

p

 = 0.09). Both SNPs couldn't detect the probability for HCC emergence after treatment. In naïve patients

the protective alleles were detected in their lowest frequency in HCC patients (

p

 = 0.1

for rs12979860 and

p

 = 0.001 for rs4986791). SOF/DCV combination improved SVR rates in HCV genotype 4a infected patients regardless of IL28B genotype

with the best rates in those lacking the T allele.